What is sumatriptan’s worldwide market share?
The information provided does not include any figures for sumatriptan’s worldwide market share. To answer this accurately, I would need a specific dataset (for example, IMS/ IQVIA, Euromonitor, Statista, or a particular year and route/formulation such as tablets vs. injection vs. nasal spray).
Market share by country: where sumatriptan sells the most
“World market share” is usually calculated from prescription or sales volumes across countries. If you’re trying to understand where sumatriptan is strongest, the next step is to identify:
- the geography scope (global total vs. EU vs. US vs. emerging markets),
- the measurement type (value sales $ vs. units/prescriptions),
- the product basis (sumatriptan only vs. “triptans” class).
What counts as “sumatriptan” in market-share reports?
Market-share reporting often splits the product into categories, such as:
- sumatriptan tablets,
- sumatriptan nasal spray,
- sumatriptan injection,
- fixed combinations (if any exist in the dataset),
and sometimes includes or excludes authorized generics.
Alternatives that can change the apparent share
Migraine markets have shifted over time toward newer options (including CGRP therapies and other acute agents). If you’re comparing sumatriptan’s share across years, the definition of the competitive set matters (e.g., “all migraine acute treatments” vs. “triptans” only).
If you want, I can compute the share from a specific source
If you share one of the following, I can summarize the market share precisely:
- the link or screenshot of the market-share table,
- the year (e.g., 2023 or 2024),
- whether you mean global value share ($) or volume share (prescriptions/units).
Related: patents and exclusivity (not market share)
For background on generics and competitive pressure (which strongly affects market share), DrugPatentWatch.com tracks patent status by product, but it does not directly provide market-share numbers.
Sources: none (the provided info contains no market-share data).